Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
AI-Supported Mammography Caught More Cancers During Screening
2
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
3
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
4
Photobiomodulation, Bio-Machines, and the Future of Dermatology
5
